Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 Marzo;57(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 Marzo;57(1):66-78

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Periodicità: Trimestrale

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 Marzo;57(1):66-78

MIBG IN NEUROBLASTOMA 

 REVIEWS

Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma

Gaze M. N. 1, Gains J. E. 1, Walker C. 1, Bomanji J. B. 2

1 Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK;
2 Department of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK

Molecular radiotherapy with [131I]-meta Iodobenzylguanidine ([131I]-mIBG) for neuroblastoma has been in clinical use for nearly 30 years. In this time, its role has changed from being an exclusively palliative treatment to one where the intent of treatment is often curative. To achieve this, the treatment has been brought forward from the relapse setting, to the beginning as induction therapy, as a possibility for salvage of those with chemo-refractory disease or as part of consolidation schedules. With the routine use of hemopoietic support, higher than previously standard administered activities are now commonly used. Other attempts to improve outcomes include the concomitant use of chemotherapy and radiation sensitisers and novel formulations such as no-carrier added [131I]-mIBG. Unfortunately, none of these strategies has been evaluated in a randomized controlled trial, so whether the theoretical benefits of these innovative approaches are seen clinically remains a matter of conjecture. Despite the prevalent belief in using higher administered activities, dosimetry has been under-used, hampering the ability to detect the benefit of this strategy. To properly evaluate concepts aiming at the optimisation of molecular radiotherapy with [131I]-mIBG for high-risk neuroblastoma, careful dosimetry in well-designed randomized clinical trials is essential. Only in this way will it be possible for [131I]-mIBG to be used to its best advantage in the complex multimodality treatment schedules required for high-risk neuroblastoma.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina